Olopatadine nasal spray for the treatment of allergic rhinitis

Abstract

Olopatadine hydrochloride nasal spray (Patanase^® Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H₁-receptor antagonist activity. Clinical trials of olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.

Keywords::

• allergic rhinitis
• allergic rhinosinusitis
• antihistamine
• mast cell stabilizer
• nasal spray
• olopatadine hydrochloride
• Patanase^®

Financial & competing interests disclosure

Peter S Roland and Bradley F Marple are paid consultants for Alcon. G Michael Wall is an Alcon employee. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.